Horien Biochemical Technology Co Ltd
Horien Biochemical Technology Co Ltd operates in the healthcare services and equipment industry, focusing on medical equipment, supplies, and distribution.
Business. Horien Biochemical Technology Co Ltd (7814.TWO) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. It is listed on the Taiwan Premium Exchange (TPEx) under the ticker 7814.TWO. Specific details regarding operating segments and geographic revenue mix are not disclosed.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Horien Biochemical Technology Co Ltd (7814.TWO) is a healthcare services and equipment company primarily engaged in the medical equipment, supplies, and distribution industry. The firm operates on a product-sale revenue model, focusing on the provision of medical devices and related supplies. It is listed on the Taiwan Premium Exchange (TPEx) under the ticker 7814.TWO. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Horien Biochemical Technology Co Ltd has a market capitalization of 1,680,000,000 TWD, with a market price of 42.0 TWD per share. The company has 40,000,000 basic and diluted shares outstanding, indicating no immediate dilution pressure from share issuance. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and return metrics are not available in the provided data, making it difficult to compare with industry_config preferred metrics or cohort medians. Without specific data on revenue, net income, or return on invested capital, a detailed profitability analysis cannot be conducted.
Segment and geographic exposure details are not disclosed in the available data, so it is not possible to assess revenue concentration or geographic diversification.
Growth trajectory data is limited, as the outlook for the current and next fiscal years, along with numeric deltas, are not provided. Historical revenue data is also missing, preventing a comprehensive growth analysis.
Risk factors include the inability to assess liquidity risk, which could impact the company's operational flexibility. The dilution potential is currently low, as there is no evidence of dilutive events in the near term.
Recent events, such as filings or transcripts, are not disclosed in the available data, so no specific recent developments can be reported.
- Horien Biochemical Technology Co Ltd operates in the medical equipment, supplies, and distribution industry.
- The company has a market capitalization of 1,680,000,000 TWD with no immediate dilution pressure.
- Liquidity risk could not be assessed due to missing balance-sheet inputs and no going-concern language in source documents.
- Profitability and return metrics are not available, making it difficult to compare with industry benchmarks.
- Growth trajectory and historical revenue data are not provided, limiting the ability to assess the company's growth potential.
- Recent events and filings are not disclosed, so no specific recent developments can be reported.
- margin_outlook_rationale: No data is available to determine the direction or driver of margin outlook.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Horien Biochemical Technology Co Ltd Market data — financials · 2026-05-27